BG64580B1 - Фармацевтичен състав, съдържащ лиофилизирани липозоми, включващи трудно разтворимо във вода активно вещество и метод за получаването на този състав - Google Patents
Фармацевтичен състав, съдържащ лиофилизирани липозоми, включващи трудно разтворимо във вода активно вещество и метод за получаването на този състав Download PDFInfo
- Publication number
- BG64580B1 BG64580B1 BG103738A BG10373899A BG64580B1 BG 64580 B1 BG64580 B1 BG 64580B1 BG 103738 A BG103738 A BG 103738A BG 10373899 A BG10373899 A BG 10373899A BG 64580 B1 BG64580 B1 BG 64580B1
- Authority
- BG
- Bulgaria
- Prior art keywords
- liposomes
- trehalose
- temperature
- active substance
- lyophilization
- Prior art date
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title claims description 20
- 239000013543 active substance Substances 0.000 title description 14
- 239000008194 pharmaceutical composition Substances 0.000 title description 4
- 239000000203 mixture Substances 0.000 claims abstract description 55
- 238000004108 freeze drying Methods 0.000 claims abstract description 34
- 150000002632 lipids Chemical class 0.000 claims abstract description 32
- 229940088623 biologically active substance Drugs 0.000 claims abstract description 17
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims description 37
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims description 37
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims description 36
- 238000007710 freezing Methods 0.000 claims description 28
- 230000008014 freezing Effects 0.000 claims description 28
- 150000003904 phospholipids Chemical class 0.000 claims description 16
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 claims description 12
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 claims description 12
- 229960003987 melatonin Drugs 0.000 claims description 12
- 229930105110 Cyclosporin A Natural products 0.000 claims description 6
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 6
- 108010036949 Cyclosporine Proteins 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 229960001265 ciclosporin Drugs 0.000 claims description 6
- WDRYRZXSPDWGEB-UHFFFAOYSA-N lonidamine Chemical compound C12=CC=CC=C2C(C(=O)O)=NN1CC1=CC=C(Cl)C=C1Cl WDRYRZXSPDWGEB-UHFFFAOYSA-N 0.000 claims description 6
- 229960003538 lonidamine Drugs 0.000 claims description 6
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 150000003626 triacylglycerols Chemical class 0.000 claims description 3
- -1 diglycerides Chemical class 0.000 claims description 2
- 125000002519 galactosyl group Chemical group C1([C@H](O)[C@@H](O)[C@@H](O)[C@H](O1)CO)* 0.000 claims description 2
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims description 2
- 125000005456 glyceride group Chemical group 0.000 claims description 2
- 150000002327 glycerophospholipids Chemical class 0.000 claims description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 239000012071 phase Substances 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- 238000010438 heat treatment Methods 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 8
- 238000001125 extrusion Methods 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 229920000515 polycarbonate Polymers 0.000 description 7
- 239000004417 polycarbonate Substances 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- 239000001307 helium Substances 0.000 description 6
- 229910052734 helium Inorganic materials 0.000 description 6
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 6
- 239000007789 gas Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000006703 hydration reaction Methods 0.000 description 2
- 239000011261 inert gas Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- RYCNUMLMNKHWPZ-SNVBAGLBSA-N 1-acetyl-sn-glycero-3-phosphocholine Chemical compound CC(=O)OC[C@@H](O)COP([O-])(=O)OCC[N+](C)(C)C RYCNUMLMNKHWPZ-SNVBAGLBSA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 125000000647 trehalose group Chemical group 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT97MI000362A IT1289938B1 (it) | 1997-02-20 | 1997-02-20 | Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e |
| PCT/EP1998/000817 WO1998036736A1 (en) | 1997-02-20 | 1998-02-12 | Pharmaceutical preparation comprising lyophilized liposomes encapsulating an active principle which is highly insoluble in water, and the process for preparing the said preparation |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BG103738A BG103738A (en) | 2000-05-31 |
| BG64580B1 true BG64580B1 (bg) | 2005-08-31 |
Family
ID=11376097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BG103738A BG64580B1 (bg) | 1997-02-20 | 1999-09-16 | Фармацевтичен състав, съдържащ лиофилизирани липозоми, включващи трудно разтворимо във вода активно вещество и метод за получаването на този състав |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US6319517B1 (enExample) |
| EP (1) | EP0981332B1 (enExample) |
| JP (1) | JP4290767B2 (enExample) |
| KR (1) | KR100496802B1 (enExample) |
| CN (1) | CN1089581C (enExample) |
| AR (1) | AR011681A1 (enExample) |
| AT (1) | ATE285754T1 (enExample) |
| AU (1) | AU744115B2 (enExample) |
| BG (1) | BG64580B1 (enExample) |
| CA (1) | CA2288958C (enExample) |
| CZ (1) | CZ295998B6 (enExample) |
| DE (1) | DE69828394T2 (enExample) |
| EA (1) | EA001637B1 (enExample) |
| ES (1) | ES2235320T3 (enExample) |
| GE (1) | GEP20022734B (enExample) |
| HU (1) | HU225593B1 (enExample) |
| IL (1) | IL131327A (enExample) |
| IT (1) | IT1289938B1 (enExample) |
| PL (1) | PL190628B1 (enExample) |
| PT (1) | PT981332E (enExample) |
| SK (1) | SK282931B6 (enExample) |
| TR (1) | TR199902025T2 (enExample) |
| UA (1) | UA70296A (enExample) |
| WO (1) | WO1998036736A1 (enExample) |
| ZA (1) | ZA981352B (enExample) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU762944B2 (en) | 1999-06-23 | 2003-07-10 | Cornell Research Foundation Inc. | Dehydration/rehydration of marked liposomes on a test device |
| US6576460B1 (en) | 1999-10-28 | 2003-06-10 | Cornell Research Foundation, Inc. | Filtration-detection device and method of use |
| EP1610778A4 (en) * | 2003-01-17 | 2006-05-31 | Threshold Pharmaceuticals Inc | TREATMENT OF BENIGNER PROSTATE HYPERPLASIA |
| MX2007012762A (es) | 2005-04-12 | 2008-01-14 | Elan Pharma Int Ltd | Composiciones de material nanoparticulado y de liberacion controlada que comprende ciclosporina. |
| WO2008036979A2 (en) * | 2006-09-22 | 2008-03-27 | Guilford F Timothy | Topical application of melatonin directly or in liposomes for the amelioration of itching and histamine and non-histamine related inflammatory skin changes |
| CN101049504B (zh) * | 2007-04-05 | 2010-05-19 | 广州立恩生物科技有限公司 | 一种脂质体药物载体及其制备方法 |
| US9446147B2 (en) | 2011-02-24 | 2016-09-20 | The Ohio State University | Membrane stabilizing compositions and methods |
| CA2852777C (en) | 2011-10-21 | 2020-10-27 | Celator Pharmaceuticals Inc. | Lyophilized liposomes |
| US8999292B2 (en) | 2012-05-01 | 2015-04-07 | Translatum Medicus Inc. | Methods for treating and diagnosing blinding eye diseases |
| WO2014035206A2 (ko) * | 2012-08-31 | 2014-03-06 | 중앙대학교 산학협력단 | 색전용 마이크로스피어의 제조방법 및 약물 함유 나노수송체가 결합된 마이크로스피어의 제조방법 |
| US10722465B1 (en) | 2017-12-08 | 2020-07-28 | Quicksilber Scientific, Inc. | Transparent colloidal vitamin supplement |
| US11344497B1 (en) | 2017-12-08 | 2022-05-31 | Quicksilver Scientific, Inc. | Mitochondrial performance enhancement nanoemulsion |
| KR102649069B1 (ko) | 2018-05-31 | 2024-03-19 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 안면 홍조 개선용 조성물 |
| EP3813862A1 (en) * | 2018-06-27 | 2021-05-05 | Breath Therapeutics GmbH | Inhalable compositions comprising macrocyclic immunosuppressants |
| EA202092893A1 (ru) | 2018-06-27 | 2021-04-19 | Брес Терапьютикс Гмбх | Фармацевтические композиции в лиофилизированной форме |
| WO2020027466A1 (ko) * | 2018-07-28 | 2020-02-06 | 주식회사 엑소코바이오 | 엑소좀의 동결건조 방법 |
| KR102163806B1 (ko) | 2018-07-30 | 2020-10-07 | 주식회사 엑소코바이오 | 줄기세포 유래의 엑소좀을 유효성분으로 포함하는 피지분비 감소용 조성물 |
| EA202092892A1 (ru) | 2018-12-04 | 2021-05-27 | Брес Терапьютикс Гмбх | Ингаляционные композиции, содержащие макроциклические иммуносупрессанты |
| US11291702B1 (en) | 2019-04-15 | 2022-04-05 | Quicksilver Scientific, Inc. | Liver activation nanoemulsion, solid binding composition, and toxin excretion enhancement method |
| EP3990433A4 (en) | 2019-06-25 | 2023-07-26 | Translatum Medicus Inc. | METHODS FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES |
| CN111358955B (zh) * | 2020-04-01 | 2023-05-02 | 重庆理工大学 | 一种用于治疗脂质代谢疾病的炎症靶向的宾达利纳米粒、制备方法及其应用 |
| JP7508359B2 (ja) * | 2020-12-11 | 2024-07-01 | 株式会社東芝 | 脂質粒子の製造方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4857319A (en) * | 1985-01-11 | 1989-08-15 | The Regents Of The University Of California | Method for preserving liposomes |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1173360A (en) * | 1979-06-22 | 1984-08-28 | Jurg Schrank | Pharmaceutical preparations |
| FR2542749B1 (fr) * | 1983-03-18 | 1985-07-12 | Beghin Say Sa | Copolymere allyloligosaccharide-acrylique salifie, procede de preparation du copolymere et application comme super-absorbant |
| US4963362A (en) * | 1987-08-07 | 1990-10-16 | Regents Of The University Of Minnesota | Freeze-dried liposome mixture containing cyclosporin |
| US5683714A (en) * | 1991-04-19 | 1997-11-04 | Nexstar Pharmaceuticals, Inc. | Liposomal cyclosporin pharmaceutical formulation |
| US5817336A (en) * | 1993-04-02 | 1998-10-06 | Orion-Yhtyma Oy | Composition containing selegiline |
| GB9320668D0 (en) * | 1993-10-07 | 1993-11-24 | Secr Defence | Liposomes containing particulare materials |
| AU683957B2 (en) * | 1993-11-05 | 1997-11-27 | Amgen, Inc. | Liposome preparation and material encapsulation method |
-
1997
- 1997-02-20 IT IT97MI000362A patent/IT1289938B1/it active IP Right Grant
-
1998
- 1998-02-12 WO PCT/EP1998/000817 patent/WO1998036736A1/en not_active Ceased
- 1998-02-12 KR KR10-1999-7007538A patent/KR100496802B1/ko not_active Expired - Fee Related
- 1998-02-12 US US09/367,715 patent/US6319517B1/en not_active Expired - Lifetime
- 1998-02-12 SK SK1110-99A patent/SK282931B6/sk not_active IP Right Cessation
- 1998-02-12 DE DE69828394T patent/DE69828394T2/de not_active Expired - Lifetime
- 1998-02-12 CN CN98802737A patent/CN1089581C/zh not_active Expired - Fee Related
- 1998-02-12 PT PT98910659T patent/PT981332E/pt unknown
- 1998-02-12 TR TR1999/02025T patent/TR199902025T2/xx unknown
- 1998-02-12 JP JP53622898A patent/JP4290767B2/ja not_active Expired - Fee Related
- 1998-02-12 EP EP98910659A patent/EP0981332B1/en not_active Expired - Lifetime
- 1998-02-12 CZ CZ19992925A patent/CZ295998B6/cs not_active IP Right Cessation
- 1998-02-12 IL IL13132798A patent/IL131327A/en not_active IP Right Cessation
- 1998-02-12 CA CA002288958A patent/CA2288958C/en not_active Expired - Fee Related
- 1998-02-12 ES ES98910659T patent/ES2235320T3/es not_active Expired - Lifetime
- 1998-02-12 GE GEAP19984991A patent/GEP20022734B/en unknown
- 1998-02-12 HU HU0001464A patent/HU225593B1/hu not_active IP Right Cessation
- 1998-02-12 UA UA99095150A patent/UA70296A/uk unknown
- 1998-02-12 EA EA199900751A patent/EA001637B1/ru not_active IP Right Cessation
- 1998-02-12 AT AT98910659T patent/ATE285754T1/de active
- 1998-02-12 PL PL98335207A patent/PL190628B1/pl unknown
- 1998-02-12 AU AU64969/98A patent/AU744115B2/en not_active Ceased
- 1998-02-18 ZA ZA981352A patent/ZA981352B/xx unknown
- 1998-02-20 AR ARP980100754A patent/AR011681A1/es active IP Right Grant
-
1999
- 1999-09-16 BG BG103738A patent/BG64580B1/bg unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4857319A (en) * | 1985-01-11 | 1989-08-15 | The Regents Of The University Of California | Method for preserving liposomes |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BG64580B1 (bg) | Фармацевтичен състав, съдържащ лиофилизирани липозоми, включващи трудно разтворимо във вода активно вещество и метод за получаването на този състав | |
| JP2579625B2 (ja) | 改良された取り込み効率を有するマルチラメラリポソ−ム | |
| JP3267611B2 (ja) | リポソーム−ポリエンプレリポソーム粉末とその製造方法 | |
| JPS60231609A (ja) | リポソ−ム製剤 | |
| CA2285985C (en) | A method for preparing aqueous liposomal compositions comprising an active ingredient which is highly insoluble in water | |
| CA2279259A1 (en) | Pain reducing parenteral liposome formulation | |
| HK1026148B (en) | Pharmaceutical preparation comprising lyophilized liposomes encapsulating an active principle which is highly insoluble in water, and the process for preparing the said preparation | |
| MXPA99007684A (en) | Pharmaceutical preparation comprising lyophilized liposomes encapsulating an active principle which is highly insoluble in water, and the process for preparing thesaid preparation | |
| MXPA99007683A (en) | Aqueous pharmaceutical composition comprising an active ingredient which is highly insoluble in water |